SCHEMBL14376567

SCHEMBL14376567

COc1ccc2c(c1)/C(=C/c1ncc(C)[nH]1)C(=O)N2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLK2 Q86UE8 7/20 0.66
▸ RET P07949 6/20 0.64
▸ CDK2 P24941 4/20 0.63
▸ CDK1 P06493 2/20 0.63
▸ MAPK1 P28482 2/20 0.63
▸ KDR P35968 2/20 0.63
▸ GSK3A P49840 2/20 0.63
▸ GSK3B P49841 2/20 0.63
▸ CDK7 P50613 2/20 0.63
▸ CDK9 P50750 2/20 0.63
▸ CDK5 Q00535 2/20 0.63
▸ CCNE1 P24864 2/20 0.63
▸ PDPK1 O15530 2/20 0.63
▸ PLK4 O00444 1/20 0.63
▸ CHEK1 O14757 1/20 0.63
▸ AURKA O14965 1/20 0.63
▸ JAK2 O60674 1/20 0.63
▸ ROCK2 O75116 1/20 0.63
▸ MAP4K4 O95819 1/20 0.63
▸ CHEK2 O96017 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14375844 0.88 TLK2 (0.52) TLK2RETCDK2CDK1MAPK1
SCHEMBL15896535 0.87 LRRK2 (0.70) TLK2RETCDK2CDK1MAPK1
SCHEMBL14375862 0.86 RET (0.67) TLK2RETCDK2CDK1MAPK1
SCHEMBL14376387 0.83 MEN1 (0.57) TLK2RETCDK2KDRCCNE1
SCHEMBL14375845 0.83 RET (0.62) RETRPS6KA3PDGFRBLRRK2MDM2
SCHEMBL14376565 0.82 TLK2 (0.64) TLK2RETCDK2CDK1MAPK1
SCHEMBL15878619 0.81 LRRK2 (0.78) TLK2RETCDK2CDK1MAPK1
SCHEMBL14376348 0.81 LRRK2 (0.78) TLK2RETCDK2CDK1MAPK1
SCHEMBL15896534 0.80 SRC (0.46) TLK2RETKDRPDPK1FGFR1
SCHEMBL6001190 0.80 MAPT (0.64) TLK2RETMAPK1KDRGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140205537-A1 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2014-07-24 — — US disclosed
WO-2012178015-A2 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2012-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140205537-A1 LRRK2 INHIBITORS LRRK2, PARK7, MAP2 TLK2 35/4885RET 789/4885CDK2 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback